BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...
BC Extra | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

Inscripta raises $125M series D  Inscripta Inc. raised $125 million in a series D round led by existing investor Paladin Capital, bringing the total capital raised by the company to $260 million since 2015. New...
BC Extra | Nov 15, 2019
Company News

BeiGene enters U.S. market with first approval for in-house pipeline

With its first approval for an internally developed drug, BeiGene faces tough competition as it seeks to carve out a niche for Brukinsa. But the third-to-market Btk inhibitor could have an edge on efficacy without...
BC Extra | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until...
BC Extra | Aug 23, 2019
Company News

BeiGene's first U.S. NDA tests global development strategy

BeiGene believes inclusion of data from trials run in China in the company’s first NDA to be reviewed by FDA could help build industry’s confidence in doing trials in China. BeiGene also hopes the strategy...
BC Extra | Jul 10, 2019
Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

As it gears up to enter the clinic next quarter, neurodegeneration company Yumanity hired Richard Peters as CEO to succeed Tony Coles, aiming to leverage Peters’ experience managing neurology trials into at least three clinical...
BioCentury | Aug 4, 2018
Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BC Week In Review | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
BC Extra | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
Items per page:
1 - 10 of 1184
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...
BC Extra | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

Inscripta raises $125M series D  Inscripta Inc. raised $125 million in a series D round led by existing investor Paladin Capital, bringing the total capital raised by the company to $260 million since 2015. New...
BC Extra | Nov 15, 2019
Company News

BeiGene enters U.S. market with first approval for in-house pipeline

With its first approval for an internally developed drug, BeiGene faces tough competition as it seeks to carve out a niche for Brukinsa. But the third-to-market Btk inhibitor could have an edge on efficacy without...
BC Extra | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until...
BC Extra | Aug 23, 2019
Company News

BeiGene's first U.S. NDA tests global development strategy

BeiGene believes inclusion of data from trials run in China in the company’s first NDA to be reviewed by FDA could help build industry’s confidence in doing trials in China. BeiGene also hopes the strategy...
BC Extra | Jul 10, 2019
Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

As it gears up to enter the clinic next quarter, neurodegeneration company Yumanity hired Richard Peters as CEO to succeed Tony Coles, aiming to leverage Peters’ experience managing neurology trials into at least three clinical...
BioCentury | Aug 4, 2018
Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BC Week In Review | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
BC Extra | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
Items per page:
1 - 10 of 1184